Novavax' RSV-influenza combination vaccine
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2014
Price : $35 *
At a glance
- Drugs Respiratory syncytial virus-influenza virus vaccine (Primary)
- Indications Influenza virus infections; Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novavax
- 06 Aug 2014 According to a Novavax media release, this trial is expected to begin in early 2015.
- 09 Oct 2013 Data from this combination respiratory syncytial virus-influenza virus vaccine trial are expected to be reported in the fourth quarter of 2014, according to Novavax.
- 09 Oct 2013 New trial record